File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Arimidex inhibition on proliferation of human breast solid tumors measured by ATP bioluminescence

TitleArimidex inhibition on proliferation of human breast solid tumors measured by ATP bioluminescence
Authors
KeywordsArimidex
ATP bioluminescence
Estrogen receptor
Human epidermal growth factor receptor-2
Progesterone receptor
Issue Date2004
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/lifescie
Citation
Life Sciences, 2004, v. 76 n. 7, p. 827-834 How to Cite?
AbstractTo determine the degree of Arimidex (Anastrozole) inhibition on proliferation of human breast solid tumors in vitro by ATP bioluminescence assay. Breast cancer solid tumors with different hormone receptors and grading were collected from 38 Chinese women with invasive breast cancers. Tumors were treated with three concentrations of Arimidex (1.5 mM, 15 mM and 150 mM). ATP bioluminescence assay was used to measure the metabolic rate in order to determine the degree of inhibition of Arimidex on the breast cancer tumors by comparing to the untreated tumors. 15 mM Arimidex shows greatest inhibitory effect on the proliferation of solid tumors with ER-postive/PR-positive. It can also inhibit the growth of metastatic tumors and tumors with HER-2/neu expression. It shows greater inhibitory effect in lower grading of tumors then higher. Arimidex may effectively inhibit the growth of breast tumors in in vitro system by inhibiting aromatase and block estrogen dependent tumor growth.
Persistent Identifierhttp://hdl.handle.net/10722/152860
ISSN
2021 Impact Factor: 6.780
2020 SCImago Journal Rankings: 1.131
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTse, EYTen_US
dc.contributor.authorLoo, WTYen_US
dc.contributor.authorCheung, MNBen_US
dc.contributor.authorChow, LWCen_US
dc.contributor.authorCheng, CWen_US
dc.date.accessioned2012-07-16T09:50:59Z-
dc.date.available2012-07-16T09:50:59Z-
dc.date.issued2004en_US
dc.identifier.citationLife Sciences, 2004, v. 76 n. 7, p. 827-834en_US
dc.identifier.issn0024-3205-
dc.identifier.urihttp://hdl.handle.net/10722/152860-
dc.description.abstractTo determine the degree of Arimidex (Anastrozole) inhibition on proliferation of human breast solid tumors in vitro by ATP bioluminescence assay. Breast cancer solid tumors with different hormone receptors and grading were collected from 38 Chinese women with invasive breast cancers. Tumors were treated with three concentrations of Arimidex (1.5 mM, 15 mM and 150 mM). ATP bioluminescence assay was used to measure the metabolic rate in order to determine the degree of inhibition of Arimidex on the breast cancer tumors by comparing to the untreated tumors. 15 mM Arimidex shows greatest inhibitory effect on the proliferation of solid tumors with ER-postive/PR-positive. It can also inhibit the growth of metastatic tumors and tumors with HER-2/neu expression. It shows greater inhibitory effect in lower grading of tumors then higher. Arimidex may effectively inhibit the growth of breast tumors in in vitro system by inhibiting aromatase and block estrogen dependent tumor growth.-
dc.languageengen_US
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/lifescie-
dc.relation.ispartofLife Sciencesen_US
dc.subjectArimidex-
dc.subjectATP bioluminescence-
dc.subjectEstrogen receptor-
dc.subjectHuman epidermal growth factor receptor-2-
dc.subjectProgesterone receptor-
dc.subject.meshAdenosine Triphosphatases - analysis - metabolism-
dc.subject.meshAntineoplastic Agents, Hormonal - pharmacology-
dc.subject.meshAromatase Inhibitors - pharmacology-
dc.subject.meshBreast Neoplasms - drug therapy - enzymology - pathology-
dc.subject.meshCarcinoma, Ductal, Breast - drug therapy - enzymology - pathology-
dc.titleArimidex inhibition on proliferation of human breast solid tumors measured by ATP bioluminescenceen_US
dc.typeArticleen_US
dc.identifier.emailTse, EYT: edithtse@graduate.hku.hken_US
dc.identifier.emailLoo, WTY: tyloo@hku.hken_US
dc.identifier.emailChow, LWC: lwcchow@hkucc.hku.hken_US
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.lfs.2004.09.016-
dc.identifier.pmid15581914-
dc.identifier.scopuseid_2-s2.0-9644308242-
dc.identifier.hkuros96744en_US
dc.identifier.volume76en_US
dc.identifier.issue7-
dc.identifier.spage827en_US
dc.identifier.epage834en_US
dc.identifier.isiWOS:000226227500011-
dc.publisher.placeUnited States-
dc.identifier.issnl0024-3205-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats